Today’s action to limit the use of Evusheld prevents exposing patients to possible side effects such as allergic reactions, which can be potentially serious, at a time when fewer than 10% of circulating variants in the U.S. causing infection are susceptible to the product.
Quote Tweet
Based on today’s revision to the Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab), it is not currently authorized for emergency use in the U.S. fda.gov/drugs/drug-saf
Show this thread
read image description
ALT
3
2
Show this thread












